{"id":"cem-101","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1232510","moleculeType":"Small molecule","molecularWeight":"845.02"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting HDAC6, CEM-101 disrupts the interaction between HDAC6 and microtubules, leading to the accumulation of acetylated microtubules and the induction of apoptosis in cancer cells. This mechanism of action is thought to contribute to the antitumor activity of CEM-101.","oneSentence":"CEM-101 is a potent and selective inhibitor of the histone deacetylase 6 (HDAC6) enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:35.340Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT02628769","phase":"PHASE2","title":"A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2015-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":6},{"nctId":"NCT02348424","phase":"PHASE1","title":"Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-05-05","conditions":"Gonorrhoea","enrollment":28},{"nctId":"NCT02605122","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia","status":"TERMINATED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2016-04","conditions":"Community-acquired Bacterial Pneumonia","enrollment":97},{"nctId":"NCT02210325","phase":"PHASE3","title":"Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2014-08","conditions":"Uncomplicated Urogenital Gonorrhea","enrollment":264},{"nctId":"NCT02268279","phase":"PHASE1","title":"Pharmacokinetics and Safety of Solithromycin in Adolescents and Children","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2015-01","conditions":"Bacterial Infection","enrollment":84},{"nctId":"NCT02510599","phase":"PHASE2","title":"Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2015-12","conditions":"Nonalcoholic Steatohepatitis","enrollment":10},{"nctId":"NCT01756339","phase":"PHASE3","title":"Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2012-12","conditions":"Community-acquired Bacterial Pneumonia","enrollment":860},{"nctId":"NCT01968733","phase":"PHASE3","title":"Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2013-11","conditions":"Community-acquired Bacterial Pneumonia","enrollment":863},{"nctId":"NCT01591447","phase":"PHASE2","title":"Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2012-05","conditions":"Uncomplicated Urogenital Gonorrhea","enrollment":60},{"nctId":"NCT01168713","phase":"PHASE2","title":"Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2010-08","conditions":"Community-Acquired Bacterial Pneumonia","enrollment":132},{"nctId":"NCT01966055","phase":"PHASE1","title":"Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2013-12","conditions":"Bacterial Infections","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Solithromycin"],"phase":"phase_2","status":"active","brandName":"CEM-101","genericName":"CEM-101","companyName":"Melinta Therapeutics, Inc.","companyId":"melinta-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CEM-101 is a potent and selective inhibitor of the histone deacetylase 6 (HDAC6) enzyme. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}